Jubilant Pharmova Limited has informed the Exchange about General Updates
JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.9 pts more than Nifty Smallcap 250 and 0.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Jubilant Pharmova announced that the USFDA has completed an audit of its Montreal, Canada-based contract manufacturing facility operated by Jubilant HollisterStier General Partnership (JHSGP) on November 3, 2025. The USFDA issued 9 observations following the inspection, and the company stated it will submit an action plan to address them. The Montreal facility is part of Jubilant Pharmova's CDMO Sterile Injectables business, serving regulated markets including the US and Europe. JHSGP is jointly owned by subsidiaries of Jubilant Pharma Limited, a wholly-owned subsidiary of Jubilant Pharmova.
Nine USFDA observations warrant close monitoring, as they typically flag procedural or compliance gaps. However, the absence of any mention of an import alert or warning letter suggests a manageable outcome, and the company's commitment to an action plan is a standard positive step. Near-term sentiment could be mildly cautious until the response is reviewed by the regulator.